^
    1d
    TNFAIP1 suppresses hepatocellular carcinoma progression via the PXR/CYP3A4 signaling axis. (PubMed, Am J Cancer Res)
    TNFAIP1 knockout not only decreased CYP3A4 expression but also significantly impaired the ability of rifampicin (RIF), an upstream nuclear receptor-pregnane X receptor (PXR) agonist, to induce CYP3A4, indicating that TNFAIP1 is an essential regulator of PXR/CYP3A4 pathway...In vivo experiments demonstrated that overexpression of Tnfaip1 upregulated the Pxr/Cyp3a11 pathway and inhibited tumor growth, whereas Tnfaip1 knockout suppressed this pathway. This study identified TNFAIP1-PXR-CYP3A4 as a novel tumor-suppressive axis in HCC, providing potential molecular targets for HCC diagnosis and treatment.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    rifampicin
    7d
    Defibrotide Dose-escalation for SOS Post-HSCT (clinicaltrials.gov)
    P2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Defitelio (defibrotide)
    9d
    CVM-008: CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=95, Recruiting, TaiRx, Inc. | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab)
    9d
    A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC (clinicaltrials.gov)
    P2, N=40, Recruiting, TaiRx, Inc.
    New P2 trial
    |
    Tyvyt (sintilimab)
    22d
    Shenling Baizhu Powder Alleviated Lung Damage and Enhanced Immunoregulatory Activity in Mice with Non-Tuberculosis Mycobacterial Lung Disease. (PubMed, Chin J Integr Med)
    SLBZP alleviated NTM-induced lung damage and enhanced NK cell immune response, which might be linked to CD4+ T cell immunity.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • GATA3 (GATA binding protein 3) • IL1B (Interleukin 1, beta)
    |
    rifampicin
    23d
    IOA-289-102: A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=16, Completed, iOnctura | Active, not recruiting --> Completed | N=24 --> 16 | Trial completion date: Mar 2026 --> Aug 2025 | Trial primary completion date: Dec 2025 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • cambritaxestat (IOA-289)
    26d
    Curcumin Synergistically Sensitizes Multidrug-Resistant Lung Cancer to Doxorubicin Through Ferroptosis-Associated Oxidative Stress. (PubMed, Antioxidants (Basel))
    Molecular docking analyses supported the binding of CUR and DOX to key ferroptosis regulators. This study shows the potential of CUR to sensitize DOX-resistant cancer cells through ferroptosis-linked-oxidative stress targeting.
    Journal
    |
    CASP3 (Caspase 3)
    |
    doxorubicin hydrochloride • curcumin/doxorubicin (iMX-110)
    28d
    Impact of rifampicin on P-glycoprotein (ABCB1) expression in M1 and M2 macrophages derived from the THP-1 monocytic cell line or peripheral blood mononuclear cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    In conclusion, ABCB1 expression in macrophages differs by the cell model (THP-1 cell line vs. primary PBMC) and the polarization phenotype (M1 vs. M2). Strong rifampicin-mediated enhancements of ABCB1 were only observed in THP-1-derived M1 and M2 cells.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • SLCO2B1 (Solute Carrier Organic Anion Transporter Family Member 2B1)
    |
    rifampicin
    30d
    RESPECT-CMV: Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University Health Network, Toronto
    New P1 trial
    1m
    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (clinicaltrials.gov)
    P3, N=674, Active, not recruiting, Queen Mary University of London | Trial completion date: Sep 2027 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    rifampicin
    1m
    PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2/3, N=120, Recruiting, N.N. Alexandrov National Cancer Centre
    New P2/3 trial
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Avastin (bevacizumab) • paclitaxel
    1m
    VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=14, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Interim analysis indicated limited efficacy
    Trial termination
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    Opdivo (nivolumab) • ofranergene obadenovec (VB-111)